We run an active and vibrant clinical research program. At Hematology-Oncology Associates of Rockland, we firmly believe that furthering the frontier of cancer knowledge will not only allow future generations of cancer patients to take advantage of more targeted, more efficacious and less toxic therapies, but it also allows current patients to have access to cutting edge therapies that may impact their disease course in real time. From a practical perspective, the ability to participate in a clinical trial, whether in a nationally recognized or NIH sponsored group, in a "close to home" setting will almost always obviate the need to travel into NYC. We work closely with the Columbia/Cornell hospital research network as well.

Our current list of active clinical research participation includes breast cancer, colorectal cancer, lung cancer, non-hodgkin's lymphoma, multiple myeloma, ovarian cancer, prostate cancer, and kidney cancer.

We maintain an active and collegial relationship with many MD's in academic positions in NYC, and many times telephonic conversations can lessen the need for travel to maximize patient comfort and convenience.

LYMPHOMA:

• "A PHASE III MULTICENTER, OPEN-LABEL STUDY OF RITUXIMAB FASTER INFUSION TIME IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL OR FOLLICULAR NON-HODGKINS LYMPHOMA"

MULTIPLE MYELOMA:

• "BONE MARKER DIRECTED DOSING OF ZOMETA FOR THE PREVENTION OF SKELETAL COMPLICATIONS IN PATIENTS WITH ADVANCED MULTIPLE MYELOMA"

LUNG CANCER:

• "MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORAL BIBF 1120 PLUS STANDARD PEMETREXED THERAPY COMPARED TO PLACEBO PLUS STANDARD PEMETREXED THERAPY IN PATIENTS WITH STAGE IIIB/IV OR RECURRENT NON-SMALL CELL LUNG CANCER AFTER FAILURE OF FIRST LINE CHEMOTHERAPY"
  


• "A MULTICENTER PHASE III RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE CANCER VACCINE STIMUVAX (L-BLP25 OR BLP25 LIPOSOME VACCINE) IN NON-SMALL CELL LUNG CANCER SUBJECTS WITH UNRESECTABLE STAGE III DISEASE"

RECTAL CANCER:

• "A CLINICAL TRIAL COMPARING PREOPERATIVE RADIATION THERAPY AND CAPECITABINE WITH OR WITHOUT OXALIPLATIN WITH PREOPERATIVE RADIATION THERAPY AND CONTINUOUS INTRAVENOUS INFUSION OF 5-FU WITH OR WITHOUT OXALIPLATIN IN THE TREATMENT OF PATIENTS WITH OPERABLE CARCINOMA OF THE RECTUM"

COLON CANCER:

• "A RANDOMIZED PHASE III TRIAL OF IRINOTECAN (CPT-11) AND/OR OXALIPLATIN PLUS 5-FLUROURACIL (5-FU)/ LEUCOVORIN (CF) WITH OR WITHOUT CETUXIMAB (C-225) AFTER CURATIVE RESECTION FOR PATIENTS WITH STAGE III COLON CANCER"
  

BREAST CANCER

• "PHASE III TRIAL OF CONTINUOUS SCHEDULED ADRIAMYCIN AND CYTOXAN  + NEULASTA  VS  EVERY 2 WEEK SCHEDULE ADRIAMYCIN AND CYTOXAN FOLLOWED BY PACLITAXEL GIVEN EVERY 2 WEEKS OR WEEKLY FOR 12 WEEKS AS POST-OPERATIVE ADJUVANT THERAPY IN NODE-POSITIVE OR HIGH RISK NODE-NEGATIVE BREAST CANCER"
  


• "A PHASE III TRIAL OF BISPHOSPHANATES AS ADJUVANT THERAPY FPR PRIMARY BREAST CANCER"
  


• "A PHASE III RANDOMIZED TRIAL OF ANASTROZOLE VERSUS ANASTROZOLE AND FULVESTRANT AS FIRST LINE THERAPY FOR POST MENOPAUSAL WOMEN WITH METASTATIC BREAST CANCER"
  


• "TAILOR RX TRIAL; ASSIGNING INDIVIDUALIZED OPTIONS FOR THE TREATMENT OF BREAST CANCER IN CONJUNCTION WITH GENETIC PROFILING FOR STAGE I ER POSITIVE BREAST CANCER"
  


• "A PHASE III OPEN LABEL, RANDOMIZED TWO-PARALLEL-ARM MULTICENTER STUDY OF E7389 VERSUS CAPECITABINE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ANTHRACYCLINES AND TAXANES AND REFRACTORY TO THE MOST RECENT CHEMOTHERAPY"
  


• "A RANDOMIZED PHASE II STUDY TO EVALUATE THE COMBINATIONS OF IXABEPILONE PLUS CAPECITABINE OR DOCETAXEL PLUS CAPECITABINE IN THE TREATMENT OF METASTATIC BREAST CANCER"
  


• "AN OPEN LABEL STUDY OF AMG 386 IN COMBINATION WITH EITHER PACLITAXEL AND TRASTUZUMAB OR CAPECITABINE AND LAPATINIB IN SUBJECTS WITH HER2 POSITIVE LOCALLY RECURRENT OR METASTATIC BREAST CANCER"
  


• "A PHASE 1/2 STUDY OF HKI-272 IN COMBINATION WITH VINORELBINE IN SUBJECTS WITH SOLID TUMORS AND METASTATIC BREAST CANCER"

OVARIAN CANCER

• "A PHASE III TRIAL OF CARBOPLATIN AND PACLITAXEL PLUS PLACEBO VERSUS CARBOPLATIN AND PACLITAXEL PLUS CONCURRRENT BEVICIZUMAB FOLLOWED BY PLACEBO VERSUS CARBOPLATIN AND PACLITAXEL PLUS CONCURRENT AND EXTENDED BEVICIZUMAB IN WOMEN WITH NEWLY DIAGNOSED, PREVIOUSLY UNTREATED, STAGE III OR IV EPITHELIAL OVARIAN, PROMARY PERITONEAL OR FALLOPIAN TUBE CANCER"

PROSTATE CANCER:

• "A RANDOMIZED DOUBLE-BLIND PHASE 3 TRIAL COMPARING DOCETAXEL COMBINED WITH DASATINIB TO DOCETAXEL COMBINED WITH PLACEBO IN CASTRATION-RESISTANT PROSTATE CANCER"
  


• "A PHASE 1b/2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF AMG 102 IN COMBINATION WITH MITOXANTRONE AND PREDNISONE IN SUBJECTS WITH PREVIOUSLY TREATED CASTRATE RESISTANT PROSTATE CANCER"

RENAL CELL CANCER:

• "ADJUVANT SORAFENIB OR SUNITINIB FOR UNFAVORABLE RENAL CELL CANCER"